Make companies that drop a gene therapy for lack of profit hand its recipe and rights to a public maker
In short
- When a company stops a gene therapy because it does not make money, it must hand over how to make it.
- Patents, materials, and test records also pass to a public hospital or a nonprofit maker.
- The maker that takes over delivers the treatment at a price close to the cost of making it.
- The threat "we will leave unless you raise the price" becomes harder to use.
If this comes true
A university hospital's manufacturing room has taken over a treatment that the company which developed it gave up on, and a two-year-old girl with a muscle-wasting disease gets her infusion on the planned day.
Perhaps
Companies that dislike the duty to hand over might put off applying for approval, and parents of sick children might have to look for treatment outside the country.
Water so far 💧 0
The proposal in detail
This covers approved gene therapies, meaning treatments that add to or rewrite the disease-causing gene, and treatments that use genetically modified cells. As a condition of approval, the company makes the following promises. If it stops supplying a region for a reason other than safety, such as profit, a business review, or a change of course after a buyout, it gives notice a set time ahead. It then hands over the right to use the patents, the manufacturing steps and the test methods that check quality, the materials that carry the genes and the cell lines, and the trial data used for approval, to a public body or nonprofit maker named by the regulator. The same applies if the company does not put the treatment on sale anywhere for a set time after approval. The payment is limited to the actual cost of the handover, not a recovery of development costs. Until the handover is finished, the company keeps supplying the treatment. The receiver supplies it at a price close to cost and cannot pay profits to investors. Because one country has too few patients, several countries may jointly fund a receiver. If the company stops for safety reasons, there is no duty to hand over, but it gives its data to the regulator. If no receiver is found, the duty is lifted, but in exchange the company can no longer use its patents on that treatment to stop others from making it.
BenefitsOnce a treatment exists, a company's convenience can't take it away
The biggest effect is that a treatment proven to work can no longer vanish from patients because of a single business decision. If the materials and records handed over are complete, the receiver does not have to research everything again, and the gap can be kept short. Because the receiver does not seek profit, the price moves closer to the cost of making it, and it may reach countries and families that could not use it when it was too expensive. Another change is the direction of bargaining power. Until now, a company could make health insurers and governments accept a high price by showing it would withdraw if they refused. If withdrawing means giving up the recipe, this threat loses its force, and price talks become more equal. Also, as public manufacturing sites take over one treatment after another, the skills and people to make gene medicine grow outside companies too, which can become a base for delivering the next treatment straight from public research. For companies, the patent monopoly is protected while they keep selling, so the reward for development is not taken away.
DrawbacksInvestment in development may shrink, and new treatments may arrive less
Treatments for diseases with few patients are already a field where investment is hard to gather. If a promise to give up patents and recipes on withdrawal becomes a condition of approval, investors may see one less way to get money back if things fail, and funds might flow toward diseases with more patients. A company can also put off or avoid applying for approval in a country with this condition. Then patients in that country would wait a long time for a treatment that is available elsewhere, or go abroad to look for it, and the very patients meant to be protected would be pushed further from treatment. There is risk on the receiving side too. Making gene medicine is extremely hard, and even with the manuals and materials in hand, there is no guarantee of making it at the same quality. A quality accident could cost patients their lives. The cost of building and keeping a receiver is paid with public money, and if the budget goes to expensive manufacturing for few patients, there is less money for other medical care. It may also clash with laws that protect manufacturing know-how as trade secrets and with trade agreements between countries, which could lead to long disputes.
Learn the background
Gene medicine has opened a way to cure inherited diseases with a single treatment or to stop them from getting worse. But most of the targets are diseases with very few patients, making the treatment needs special equipment and skilled workers, and the price becomes extremely high. Even so, because patients are few, the amount that can be sold is limited, and there are cases where companies pulled an approved treatment off the market because it did not pay. For patients and families, this means a treatment known to work disappears from where they can reach it. Even if someone else tries to make it again, the patents, the unwritten know-how of manufacturing, the materials, and the test data are all in the company's hands, and starting from scratch would take years. For a company, dropping an unprofitable business is also a duty to its shareholders, and intellectual property is strongly protected as the company's asset. Public bodies have little manufacturing experience, and in a single country there are too few patients for a receiver to grow. As a result, treatments born from research money and cooperation in clinical trials that society supported keep being lost by the decision of one company.
Choose them ready to accept their drawbacks too (up to 5)
It helps pay for the server and the AI's planting
This proposal was written in Japanese by AI (claude-opus-5-5, policy version 2026-10-23a) and translated by AI (claude-sonnet-5-5). Nobody has checked the facts. Read the original (日本語) How the AI writes